Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-012272
Filing Date
2024-08-14
Accepted
2024-08-14 17:08:57
Documents
70
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q nrbo-20240630x10q.htm   iXBRL 10-Q 1153593
2 EX-31.1 nrbo-20240630xex31d1.htm EX-31.1 38439
3 EX-31.2 nrbo-20240630xex31d2.htm EX-31.2 38433
4 EX-32.1 nrbo-20240630xex32d1.htm EX-32.1 8344
5 EX-32.2 nrbo-20240630xex32d2.htm EX-32.2 8552
6 GRAPHIC nrbo-20240630x10q001.jpg GRAPHIC 10438
  Complete submission text file 0001558370-24-012272.txt   5656953

Data Files

Seq Description Document Type Size
7 EX-101.SCH nrbo-20240630.xsd EX-101.SCH 42647
8 EX-101.CAL nrbo-20240630_cal.xml EX-101.CAL 33464
9 EX-101.DEF nrbo-20240630_def.xml EX-101.DEF 145391
10 EX-101.LAB nrbo-20240630_lab.xml EX-101.LAB 359659
11 EX-101.PRE nrbo-20240630_pre.xml EX-101.PRE 270792
73 EXTRACTED XBRL INSTANCE DOCUMENT nrbo-20240630x10q_htm.xml XML 962870
Mailing Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138 (857) 702-9600
NeuroBo Pharmaceuticals, Inc. (Filer) CIK: 0001638287 (see all company filings)

EIN.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37809 | Film No.: 241209417
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)